… ProQR to Focus Exclusively on Axiomer RNA-editing Technology and Partner Ophthalmology Programs In … to focus exclusively on the development of the Axiomer ® RNA editing technology platform across multiple therapeutic … sepofarsen and will now focus exclusively on its Axiomer ® RNA-editing technology platform. Following the results from …
… Leading Intellectual Property Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 06, … US patent No. 11,781,134 that relates to a method for RNA editing. Key claims in this patent pertain to use of any …
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025
Axiomer activity demonstrated across multiple preclinical in vitro
